KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Expenses (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Operating Expenses for 18 consecutive years, with $363.5 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses rose 30.54% year-over-year to $363.5 million; the TTM value through Mar 2026 reached $1.4 billion, up 18.56%, while the annual FY2025 figure was $1.3 billion, 12.3% up from the prior year.
  • Operating Expenses hit $363.5 million in Q1 2026 for Ionis Pharmaceuticals, down from $417.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $417.8 million in Q4 2025 and bottomed at $199.4 million in Q1 2022.
  • Average Operating Expenses over 5 years is $294.6 million, with a median of $287.5 million recorded in 2023.
  • Year-over-year, Operating Expenses surged 64.04% in 2022 and then decreased 8.14% in 2023.
  • Ionis Pharmaceuticals' Operating Expenses stood at $359.9 million in 2022, then dropped by 8.14% to $330.6 million in 2023, then rose by 2.05% to $337.4 million in 2024, then rose by 23.83% to $417.8 million in 2025, then fell by 12.99% to $363.5 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $363.5 million, $417.8 million, and $316.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.